We believe removing the T-cells from the recipient gave them the chance to recuperate and multiply it allowed the bodys defence system to regroup and re-arm itself against this deadly virus, said Associate Professor Rajiv Khanna.
When the bolstered T-cells were injected back into the patient they were accepted by their immune system as if they had been produced within the body itself. Positive results were observed after only four weeks of treatment. Six months after treatment the patient had no evidence of disease caused by the virus the HCMV had stopped replicating the virus had been beaten.
What makes this research so exciting is for the first time we have given a patient long term protection against a virus that already existed in their body but which the donor cells were unable to fight previously this was not thought possible, said Professor Hill.
We believe these findings have important implications for the use of immunotherapy for this group of transplant recipients. This treatment has the potential to save the lives of many patients worldwide.
However we have to be cautious as this procedure has only been used with one patient. The results are incredibly encouraging and the research teams at QIMR and RBWH are now embarking on a formal prospective clinical trial to thoroughly test this procedure, explained Professor Hill.
This research was supported by funding from the Leukaemia Foundation of Queensland.
The results were published in the
American Journal of Transplantation.
Source-Medindia
GPL